Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celldex Therapeutics (NQ: CLDX ) 35.27 -0.42 (-1.18%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,605,105 Open 35.88 Bid (Size) 34.00 (1) Ask (Size) 36.83 (1) Prev. Close 35.69 Today's Range 34.78 - 36.00 52wk Range 22.11 - 53.18 Shares Outstanding 65,910,548 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Celldex Therapeutics to Present at Jefferies Healthcare Conference June 04, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Analyst Expectations For Celldex Therapeutics's Future June 03, 2024 Via Benzinga Performance YTD -12.72% -12.72% 1 Month -6.37% -6.37% 3 Month -14.00% -14.00% 6 Month -6.72% -6.72% 1 Year -4.55% -4.55% More News Read More Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 June 02, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis May 15, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Unveiling 4 Analyst Insights On Celldex Therapeutics May 07, 2024 Via Benzinga CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 Via InvestorPlace Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update May 06, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria April 17, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics: Q4 Earnings Insights February 26, 2024 Via Benzinga Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics December 20, 2023 Via Benzinga Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference March 08, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 Via Benzinga Topics Stocks Exposures US Equities Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock February 29, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Announces Proposed Public Offering of Common Stock February 28, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 26, 2024 Via Benzinga Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment February 26, 2024 Via Investor's Business Daily Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update February 26, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria February 24, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 06, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 February 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Top Picks 2024: Celldex Therapeutics, Inc. January 28, 2024 Via Talk Markets Top 4 Health Care Stocks That May Crash This Month December 20, 2023 Via Benzinga Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference November 27, 2023 From Celldex Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.